Empagliflozin directly improves diastolic function in human heart failure

Cited by (225)

Items 201–225 of 225

1. Direct cardial effects and mechanisms of cardiovascular action of gliflosins
   Yakov F. Zverev, A. Ya. Rykunova · 2021 · Reviews on Clinical Pharmacology and Drug Therapy
2. Analysis of the cardiac effects of sodium-glucose co-transporter 2 inhibitors in animals without diabetes and a clinical perspective
   Elizabeth T. Oyesomi, Reza Tabrizchi · 2023 · European Journal of Pharmacology
3. Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice?
   Faiz Baqai, Masafumi Kitakaze, Yochai Birnbaum · 2024 · Cardiovascular Drugs and Therapy
4. SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
   Mukesh Nandave · 2024 · Springer eBooks
5. Cardioprotective effects of sodium-glucose transport protein 2 inhibitors in patients with breast cancer and concomitant type 2 diabetes mellitus undergoing chemotherapy
   Sergiy V. Fedorov, S. B. Herashchenko, I.V. Kozlova, M.V. Bielinskyi, Andrii S. Herashchenko, H.D. Roiko, S.A. Vahyl · 2025 · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
6. In Search of Commonality: Physiological and Therapeutic Potentials of Sodium-Glucose Transport Protein 2 Inhibitors in Cardiovascular and Chronic Kidney Diseases
   Khalid Sawalha, Lana Alamat, Aakash Rana, Landon Bruich, Angel Lopez Candales · 2025 · Cureus
7. Emerging Therapeutic Frontiers in Cardiology: What Does the Future Hold?
   Niamh Holmes · 2025 · European Medical Journal
8. Additional file 1 of Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
   Liang, Bo, Yi Liang, Gu, Ning · 2022 · Figshare
9. Additional file 1 of Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis
   Chung, Cheng-Chih, Lin, Yung-Kuo, Chen, Yao-Chang, Kao, Yu-Hsun, Yung‐Hsin Yeh, Trang, Nguyen Ngoc, Chen, Yi-Jen · 2024 · Figshare
10. Load-Dependent Effects of Sodium Glucose Co-Transporter Inhibitors on Work in Human Hypertrophic Cardiomyopathy Living Myocardial Slices
    Rebecca B. Taichman, Julia N. Smolyak, Jesse Chittams, Kelly Gallagher, Christopher M. McAllister, Jaime M. Yob, Kenneth C. Bedi, Michael P. Morley, Trisha T. Phan, Sapna N. Patel et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
11. Empagliflozin and platelet-rich plasma improve stanozolol induced cardiotoxicity by reducing NF-κB/P65, IL-1B and apoptosis
    Shaimaa M Hafez, Eman Mohammed Elsaeed, Amal Hussain Mohammed Ali, Eman Sayed Said, Yara Sayed Abouelela, Asmaa A. Elshiech, Heba Abdelnaser Aboelsoud, Hala Magdy Anwer, Samar Hassan Elsharkawy, Marwa A. Ibrahim et al. · 2026 · BMC Pharmacology and Toxicology
12. Rôle des péricytes et des cellules endothéliales dans l'insuffisance cardiaque
    Lauriane Cornuault · 2022 · theses.fr (ABES)
13. Protective effect of SGLT2 inhibitors on cardiovascular remodeling
    Kensuke Matsushita · 2022 · theses.fr (ABES)
14. Expanding the scope of SGLT inhibitors in underrepresented cardiac populations: from pathophysiology to clinical evidence
    Banmeet Padda, Jane T. Kelleher, Valtteri Muroke, Vikas S. Sridhar, Maxime Tremblay‐Gravel, Jean‐Claude Tardif, Jacinthe Boulet · 2026 · Frontiers in Cardiovascular Medicine
15. Atrial Fibrillation Increases Proarrhythmic Mechanisms in the Ventricle
    Paul Spangler, Thea Bommer, Laura Stengel, Petros Tirilomis, Thomas Körtl, Laura M. Schreiner, Thomas Sowa, Tobias Uhe, Çhristof Schmid, Zdeněk Provazník et al. · 2026 · JACC Basic to Translational Science
16. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.
    厚典 柏木, 信一 荒木, 聡 前川, Atsunori KASHIWAGI, Shin-ichi ARAKI, Hiroshi Maegawa · 2020 · Institutional Repositories DataBase (IRDB)
17. Empagliflozin–pirfenidone dual therapy improves cardiac function and structure in a preclinical two-hit HFpEF model
    Yuexin Yu, Yaping Xu, J X Chen, Yao Yao, Yingtian Liu, Tan Huang, Shaolong Yang, King‐Hwa Ling, Jacques P. Guyette, Bakiah Shaharuddin et al. · 2026 · Frontiers in Pharmacology
18. Estrogen-Deficiency Degrades Left Ventricular Diastolic Function and Energy Metabolism in Hypertensive Female Mice
    Aijun Zhang, Shumin Li, Indira Vedula, Somik Chatterjee, Yang Wu, Jianhua Gu, George Gerald Rodney, Karla Marie Kurrelmeyer, Heinrich Taegtmeyer, Dale J. Hamilton et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
19. The ‘Chloride Theory’ for Heart Failure Pathophysiology: An Updated Narrative Review 2025
    Hajime Kataoka · 2026 · Cardiology and Therapy
20. Preoperative empagliflozin and ventricular remodeling after coronary artery bypass grafting in type 2 diabetes: a prespecified analysis of the POST-CABGDM randomized trial
    Vinícius Oro Popp, Fabio Grunspun Pitta, Giovanna Daneluz de Brito, Júlia Oro Popp, LETICIA NEVES SOLON CARVALHO, Leon Pablo Cartaxo Sampaio, Fabiana Hanna Rached, Bruno Mahler Mioto, Paula Mathias Paulino Bolta, Omar Asdrúbal Vilca Mejía et al. · 2026 · Diabetology & Metabolic Syndrome
21. Chronic Kidney Disease-Associated Cardiomyopathy: Mechanisms and Therapeutic Strategies
    Konstantinos Grigoriou, Vasileios Lamprou, Anastasios Chatzichidiroglou, Panagiotis Theofilis, Panagιotis Iliakis, Anastasiοs Apostolos, Nikolaos Ktenopoulos, Efstratios Karagiannidis, Antonios P. Antoniadis, Nikolaos Fragakis et al. · 2026 · British Journal of Hospital Medicine
22. SGLT2 inhibition improves sarcomere contractile dysfunction in human models of dilated cardiomyopathy
    Daria Plota, Hafiza Nosheen Saleem, Kun-Han Lin, Ruheen Wali, Cleophas Cheruiyot, Luca Münzel, Tabea Hutschenreiter, Malte Tiburcy, Tim Meyer, Michael Habeck et al. · 2026 · Journal of Translational Medicine
23. SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives
    Jelica Grujic-Milanovic, Jovana Rajković, Radmila Novaković, Javad Sharifi‐Rad, Daniela Cornelia Călina · 2026 · Clinical and Translational Discovery
24. Complex antiarrhythmic effects of empagliflozin in non-ischemic HFrEF cardiomyocytes
    Bence Hegyi, Donald M. Bers · 2026 · Frontiers in Pharmacology
25. Effects of SGLT2 inhibition on cardiac remodeling and heart failure development in aortic stenosis rats
    Luana Urbano Pagan, Mariana Janini Gomes, Mariana Gatto, Gustavo A. F. Mota, João Pedro G. Oliveira, Felipe Cesar Damatto, Lidiane M. Souza, Eder A. Rodrigues, Anna Clara C. Santos, Gabriela H. Tukiyama et al. · 2026 · Molecular Biomedicine